Sporanox Related Published Studies
Well-designed clinical trials related to Sporanox (Itraconazole)
Efficacy of itraconazole in the treatment of patients with chronic cough whose sputa yield basidiomycetous fungi-fungus-associated chronic cough (FACC). [2009.05]
A sensitive validated LC-MS/MS method for quantification of itraconazole in human plasma for pharmacokinetic and bioequivalence study in 24 Korean volunteers. [2009.02]
Voriconazole increases while itraconazole decreases plasma meloxicam concentrations. [2009.02]
Itraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphine. [2008.11]
Examining sex-related differences in enteric itraconazole metabolism in healthy adults using grapefruit juice. [2008.03]
Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. [2008.02.05]
An open-label comparative pilot study of oral voriconazole and itraconazole for long-term treatment of paracoccidioidomycosis. [2007.12.01]
Involvement of P-glycoprotein on ivermectin kinetic behaviour in sheep: itraconazole-mediated changes on gastrointestinal disposition. [2007.06]
Effect of itraconazole on pharmacokinetics of paroxetine: the role of gut transporters. [2007.02]
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. [2007.01.25]
Pharmacokinetics of itraconazole and hydroxyitraconazole in healthy subjects after single and multiple doses of a novel formulation. [2006.12]
Pulse itraconazole vs. continuous terbinafine for the treatment of dermatophyte toenail onychomycosis in patients with diabetes mellitus. [2006.11]
Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. [2006.11]
A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. [2006.07]
Terbinafine versus itraconazole and fluconazole in the treatment of Vulvovaginal candidiasis. [2006.07]
Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide. [2006.06]
Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. [2006.05]
Combined effects of itraconazole and CYP2D6*10 genetic polymorphism on the pharmacokinetics and pharmacodynamics of haloperidol in healthy subjects. [2006.04]
An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia. [2006.02]
Study of oral itraconazole and terbinafine pulse therapy in onychomycosis. [2006.01]
Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. [2006.01]
Effect of itraconazole on the pharmacokinetics of atenolol. [2005.12]
A comparison of the efficacy between two itraconazole generic products and the innovative itraconazole in the treatment of tinea pedis. [2005.09]
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism. [2005.08]
Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide. [2005.08]
An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis. [2005.07]
Studies on itraconazole delivery and pharmacokinetics in mallard ducks (Anas platyrhynchos). [2005.06]
Reduced oral itraconazole bioavailability by antacid suspension. [2005.06]
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. [2005.05]
Simultaneous itraconazole bioequivalence assessment and CYP3A phenotyping in South American subjects. [2005.02]
Effects of itraconazole or grapefruit juice on the pharmacokinetics of telithromycin. [2005.01]
A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. [2005.01]
Pharmacokinetic drug interactions of gefitinib with rifampicin, itraconazole and metoprolol. [2005]
Clinical usefulness of oral itraconazole, an antimycotic drug, for refractory atopic dermatitis. [2004.11]
Randomized comparison between fluconazole and itraconazole for the treatment of candidemia in a pediatric intensive care unit: a preliminary study. [2004.11]
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of a single oral dose of brotizolam. [2004.11]
Clinical and mycological efficacy of single-day oral treatment with itraconazole (400 mg) in acute vulvovaginal candidosis. [2004.10]
Effect of itraconazole on the pharmacokinetics of inhaled lidocaine. [2004.09]
Inhibition of the metabolism of etizolam by itraconazole in humans: evidence for the involvement of CYP3A4 in etizolam metabolism. [2004.08]
Treatment of head and neck dermatitis comparing itraconazole 200 mg and 400 mg daily for 1 week with placebo. [2004.07]
An open multicentre comparative study of the efficacy, safety and tolerance of fluconazole and itraconazole in the treatment of cancer patients with oropharyngeal candidiasis. [2004.06]
Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. [2004.04]
Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. [2004.02.15]
Experimental Aspergillus fumigatus infection in quails and results of treatment with itraconazole. [2004.02]
Correlation of in vitro itraconazole and fluconazole susceptibility with clinical outcome for patients with vulvovaginal candidiasis. [2004.01]
Pharmacokinetics of moxifloxacin are not influenced by a 7-day pretreatment with 200 mg oral itraconazole given once a day in healthy subjects. [2004.01]
Treatment of tinea imbricata: a randomized clinical trial using griseofulvin, terbinafine, itraconazole and fluconazole. [2004.01]
[Optimal dosages and cycles of itraconazole pulse therapy for onychomycosis] [2004]
Single-dose fluconazole versus itraconazole in pityriasis versicolor. [2004]
The effect of itraconazole on the pharmacokinetics and pharmacodynamics of bromazepam in healthy volunteers. [2003.11]
Efficacy and safety of itraconazole prophylaxis for fungal infections after orthotopic liver transplantation: a prospective, randomized, double-blind study. [2003.09.27]
Fungal colonization in neutropenic patients: a randomized study comparing itraconazole solution and amphotericin B solution. [2003.09]
Effects of itraconazole on the plasma kinetics of quazepam and its two active metabolites after a single oral dose of the drug. [2003.08]
A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis. [2003.07]
Itraconazole to prevent fungal infections in chronic granulomatous disease. [2003.06.12]
Pharmacokinetics of lower doses of saquinavir soft-gel caps (800 and 1200 mg twice daily) boosted with itraconazole in HIV-1-positive patients. [2003.06]
Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. [2003.05.06]
Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial. [2003.05]
The efficacy of fluconazole 600 mg/day versus itraconazole 600 mg/day as consolidation therapy of cryptococcal meningitis in AIDS patients. [2003.04]
Effect of itraconazole on the pharmacokinetics of rosuvastatin. [2003.04]
A controlled clinical trial of itraconazole for prevention of fungal infections secondary to chemotherapy. [2003.04]
Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons. [2003.04]
Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide. [2003.03]
Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. [2003.03]
Fluconazole 150 mg single dose versus itraconazole 200 mg per day for 3 days in the treatment of acute vaginal candidiasis: a double-blind randomized study. [2003.02.10]
A randomized comparative study to determine the effect of omeprazole on the peak serum concentration of itraconazole oral solution. [2003.02]
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. [2003.01.15]
Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up. [2003.01]
A mucoadhesive, cyclodextrin-based vaginal cream formulation of itraconazole. [2003]
Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole. [2002.10]
Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. [2002.08]
Comparison of pulse administration versus once daily administration of itraconazole for the treatment of Malassezia pachydermatis dermatitis and otitis in dogs. [2002.06.15]
Comparison of a single 400 mg dose versus a 7-day 200 mg daily dose of itraconazole in the treatment of tinea versicolor. [2002.06]
No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. [2002.06]
An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis. [2002.03]
Absence of clinically relevant drug interactions following simultaneous administration of didanosine-encapsulated, enteric-coated bead formulation with either itraconazole or fluconazole. [2002.03]
Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis: a 5-year blinded prospective follow-up study. [2002.03]
Long-term results in patients with onychomycosis treated with terbinafine or itraconazole. [2002.02]
A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand. [2002.01.15]
Efficacy of itraconazole in the prophylactic treatment of pityriasis (tinea) versicolor. [2002.01]
Pharmacokinetics of intravenous itraconazole followed by itraconazole oral solution in patients with human immunodeficiency virus infection. [2001.12]
Amorolfine and itraconazole combination for severe toenail onychomycosis; results of an open randomized trial in Spain. [2001.10]
Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. [2001.09.18]
Efficacy of topical and systemic itraconazole as a broad-spectrum antifungal agent in mycotic corneal ulcer. A preliminary study. [2001.09]
Therapeutic options for the treatment of tinea capitis caused by Trichophyton species: griseofulvin versus the new oral antifungal agents, terbinafine, itraconazole, and fluconazole. [2001.09]
Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. [2001.07]
Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. [2001.05]
A randomized, double-blind, placebo-controlled study of itraconazole capsules for the prevention of deep fungal infections in immunodeficient patients with HIV infection. [2001.04]
Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole. [2001.04]
DNA fingerprinting of serial Candida albicans isolates obtained during itraconazole prophylaxis in patients with AIDS. [2001.04]
Effect of clarithromycin and itraconazole on the pharmacokinetics of ropivacaine. [2001.04]
Single-blind, randomized, prospective study of sequential itraconazole and terbinafine pulse compared with terbinafine pulse for the treatment of toenail onychomycosis. [2001.03]
Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. [2001]
Cost effectiveness of continuous terbinafine compared with intermittent itraconazole in the treatment of dermatophyte toenail onychomycosis: an analysis of based on results from the L.I.ON. study. Lamisil versus Itraconazole in Onychomycosis. [2001]
Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis. A randomized, double-blind trial. Mycoses Study Group. [2000.11.07]
Clinical trial: clotrimazole troche vs. itraconazole oral solution in the treatment of oral candidosis in AIDS patients. [2000.11]
The cytochrome P450 3A4 inhibitor itraconazole markedly increases the plasma concentrations of dexamethasone and enhances its adrenal-suppressant effect. [2000.11]
Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. [2000.10]
Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B. [2000.07]
The effect of itraconazole on the pharmacokinetics and pharmacodynamics of oral prednisolone. [2000.04]
A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. [2000.03.16]
|
